Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses

Despite major advances in first-line treatment, a significant proportion of patients with diffuse large B-cell lymphoma (DLBCL) will experience treatment failure. Prognosis is particularly poor for relapses occurring less than one year after the end of first-line treatment (early relapses/ER) compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Broséus, Julien, Chen, Gaili, Hergalant, Sébastien, Ramstein, Gérard, Mounier, Nicolas, Guéant, Jean-Louis, Feugier, Pierre, Gisselbrecht, Christian, Thieblemont, Catherine, Houlgatte, Rémi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356640/
https://www.ncbi.nlm.nih.gov/pubmed/27276707
http://dx.doi.org/10.18632/oncotarget.9793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356640/
https://www.ncbi.nlm.nih.gov/pubmed/27276707
http://dx.doi.org/10.18632/oncotarget.9793

Ejemplares similares